Affinity DataKi: 5nMAssay Description:Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 15nMAssay Description:Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 17nMAssay Description:Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 22nMAssay Description:Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 56nMAssay Description:Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 71nMAssay Description:Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 400nMAssay Description:Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 2.20E+3nMAssay Description:Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 2.50E+3nMAssay Description:Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 4.00E+3nMAssay Description:Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 4.60E+3nMAssay Description:Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 9.20E+3nMAssay Description:Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 1.30E+4nMAssay Description:Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 1.46E+4nMAssay Description:Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 1.60E+4nMAssay Description:Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataKi: 8.20E+4nMAssay Description:Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells assessed as inhibition of H2O2 production using kynuramine as subst...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
Affinity DataIC50: 100nMAssay Description:Inhibition of [3H]PAF receptor binding to washed human platelet membranes determined in vitroMore data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Kaken Pharmaceutical
US Patent
Kaken Pharmaceutical
US Patent
Affinity DataIC50: <100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair